Search Results - kenneth+berlin

2 Results

Sort By:

Metabolites of SHetA2 as Anti-Cancer Agents

BACKGROUND SHetA2 has previously been identified by OSU researchers as a strong anti-cancer agent that induces apoptosis (cell death) in 8 different types of kidney cancer cells and is being developed for treatment of Polycystic Kidney Disease (PKD). SHetA2 is in the final stages of preclinical testing and since no toxicity to normal cells has been...

Published: 10/19/2022 | Inventor(s): Doris Benbrook, Richard Bunce, Kenneth Berlin

Keywords(s): Biotech & Pharmaceutical

Category(s): Technology Classifications > Biotech & Pharmaceutical

Chroman and Tetrahydroquinoline-Derived Heteroarotinoids as Agents to Treat Human Ovarian Cancer

BACKGROUND Advanced stage malignant ovarian cancer (MOC) is an incurable disease of women, resistant to chemotherapies with agents such as cisplatin, carboplatin and taxane. MOC chemotherapies also have limited tumor specificity and cause significant toxicity, resulting in modest efficacy and recurrence in greater than 70% of treated patients. Thus,...

Published: 5/31/2023 | Inventor(s): Richard Bunce, Krishna Gnanasekaran, Field Watts, Donghua Zhou, Doris Benbrook, Kenneth Berlin

Keywords(s):

Category(s): Technology Classifications > Biotech & Pharmaceutical